EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Capital Increase
Marinomed Biotech AG resolves capital increase excluding statutory
subscription rights by issuing 61.607 no-par value bearer shares at an
issue price of EUR 17,50 per share
16-Sep-2025 / 15:22 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the
Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS
Group.
The issuer is solely responsible for the content of this announcement.
══════════════════════════════════════════════════════════════════════════
Ad hoc announcement
Marinomed Biotech AG resolves capital increase excluding statutory
subscription rights by issuing 61.607 no-par value bearer shares at an
issue price of EUR 17,50 per share
Korneuburg, September 16, 2025 - Marinomed Biotech AG (the "Company")
announces that the Management Board has resolved today to increase the
Company's share capital by EUR 61.607 to EUR 1.839.940 by issuing 61.607
new no-par value bearer shares against cash contributions. The new shares
will be issued from the authorized capital 2024/II and are subject to the
direct exclusion of the statutory subscription rights of existing
shareholders. The issue price per new share is EUR 17,50 so that the total
issue price amounts to EUR 1,078,123. The Company's Supervisory Board
approved this capital increase today, immediately after the Management
Board passed the resolution. All 61.607 new shares have been subscribed at
these issue terms and conditions by a total of nine investors.
+++ End of ad-hoc announcement +++
About Marinomed Biotech AG
Marinomed Biotech AG is an Austrian, science-based biotech company with a
growing development pipeline. The Company develops innovative
patent-protected products based on the Marinosolv® platform. The
Marinosolv® technology improves the solubility and bioavailability of
hardly soluble compounds and is used to develop new therapeutics for
autoreactive immune disorders. The Company is headquartered in Korneuburg,
Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For
further information, please visit: https://www.marinomed.com.
For further inquiries contact:
Marinomed Biotech AG
PR: Luca Horinek
IR.: Tobias Meister
T: +43 2262 90300 158
E-Mail: (1)pr@marinomed.com
E-Mail: (2)ir@marinomed.com
Disclaimer
This press release contains forward-looking statements, which are based on
current views, expectations and projections of the management of Marinomed
Biotech AG about future events. These forward-looking statements are
subject to risks, uncertainties and assumptions that could cause actual
results, performance or events to differ materially from those described
in, or expressed or implied by, such statements. The current views,
expectations and projections of the management of Marinomed Biotech AG may
be identified by the context of such statements or words such as
“anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project”
and “target”. Forward-looking statements are only valid as of the date
they are made and Marinomed Biotech AG does not assume any obligation to
update, review or revise any forward-looking statements contained in this
press release whether as a result of new information, future developments
or otherwise. Marinomed and Marinosolv® are registered trademarks of
Marinomed Biotech AG. These trademarks may be owned or licensed in select
locations only.
End of Inside Information
══════════════════════════════════════════════════════════════════════════
16-Sep-2025 CET/CEST News transmitted by EQS Group. www.eqs.com
══════════════════════════════════════════════════════════════════════════
Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Austria
Phone: +43 2262 90300
E-mail: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6
WKN: A2N9MM
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt,
Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
(Official Market)
EQS News ID: 2198258
End of Announcement EQS News Service
2198258 16-Sep-2025 CET/CEST
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2198258&application_name=news&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf
References
Visible links
1. mailto:pr@marinomed.com
2. mailto:ir@marinomed.com
OTS original text press release with the exclusive in terms of content of the sender – www.ots.at |